142217-77-4

Basic information

• Product Name: (1S,2S,3S,5S)-5-(2-Amino-6-(benzyloxy)-9H-purin-9-yl)-3-(benzyloxy)-2-(benzyloxymethyl)cyclopentanol
• Synonyms: (1S,2S,3S,5S)-5-(2-Amino-6-(benzyloxy)-9H-purin-9-yl)-3-(benzyloxy)-2-(benzyloxymethyl)cydopentanol;(1S,2S,3S,5S)-5-(2-Amino-6-(benzyloxy)-9H-purin-9-yl)-3-(benzyloxy)-2-(benzyloxymethyl)cyclopentanol;（1S,2R,3S,5S）-5-(2-amino-6-(benzyloxy)-9H-purin-9-yl)-3-(benzyloxy)-2-(benzyloxymethyl)cyclopentanol;(1S,2S,3S,5S)-5-(2-Amino-6-(benzyloxy)-9H-purin-9-yl)-3-(benzyloxy)-2-(benzyloxymethyl)cyclopentanol ,98%;Entecavir InterMediate IV;Entecavir-4;(1S,2S,3S,5S)-5-(2-AMino-6-(benzyloxy)-9H-purin-9-yl)-3-(benzyloxy)-2-(benzyloxyMethyl)cyclopentanol (interMediate step 3);(1S,2S,3S,5S)-5-(2-Amino-6-(benzyloxy)-9H-purin-9-yl)-3-(benzyloxy)-2-(benzyloxymethyl)cyclopenta
• CAS NO: 142217-77-4
• Molecular Formula: C₃₂H₃₃N₅O₄
• Molecular Weight: 551.64
• EINECS: 1312995-182-4
• Mol File: 142217-77-4.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 780.5 °C at 760 mmHg
• Flash Point: 425.8 °C
• Appearance: Colorless transparent liquid
• Density: 1.33
• Refractive Index: 1.67
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• PKA: 13.88±0.70(Predicted)
• CAS DataBase Reference: (1S,2S,3S,5S)-5-(2-Amino-6-(benzyloxy)-9H-purin-9-yl)-3-(benzyloxy)-2-(benzyloxymethyl)cyclopentanol(CAS DataBase Reference)
• NIST Chemistry Reference: (1S,2S,3S,5S)-5-(2-Amino-6-(benzyloxy)-9H-purin-9-yl)-3-(benzyloxy)-2-(benzyloxymethyl)cyclopentanol(142217-77-4)
• EPA Substance Registry System: (1S,2S,3S,5S)-5-(2-Amino-6-(benzyloxy)-9H-purin-9-yl)-3-(benzyloxy)-2-(benzyloxymethyl)cyclopentanol(142217-77-4)

Safety Data

• Hazardous Substances Data: 142217-77-4(Hazardous Substances Data)

Usage

Description

(1S,2S,3S,5S)-5-(2-Amino-6-(benzyloxy)-9H-purin-9-yl)-3-(benzyloxy)-2-(benzyloxymethyl)cyclopentanol is a cyclopentanol derivative featuring a purine moiety with an amino group and multiple benzyloxy groups. This complex compound is characterized by its chiral centers and the presence of lipophilic benzyl groups, which may contribute to its potential biological activity and pharmacokinetic properties.

Uses

Given the provided materials, there are no explicit uses listed for this specific compound. However, based on the general properties of similar compounds, we can infer potential applications:
Used in Pharmaceutical Industry:
(1S,2S,3S,5S)-5-(2-Amino-6-(benzyloxy)-9H-purin-9-yl)-3-(benzyloxy)-2-(benzyloxymethyl)cyclopentanol could be used as a pharmaceutical agent for its potential interaction with purine receptors or enzymes, which may have implications in the treatment of diseases related to purine metabolism.
Used in Drug Development Research:
In the field of drug development, this compound might serve as a lead molecule for the design of new therapeutics, given its unique structure and potential biological activity. Further research would be required to explore its efficacy and safety.
Used in Chemical Synthesis:
(1S,2S,3S,5S)-5-(2-Amino-6-(benzyloxy)-9H-purin-9-yl)-3-(benzyloxy)-2-(benzyloxymethyl)cyclopentanol could also be utilized as an intermediate in the synthesis of other complex organic molecules, particularly those with potential applications in medicinal chemistry or material science.

InChI:InChI=1/C32H33N5O4/c33-32-35-30-28(31(36-32)41-19-24-14-8-3-9-15-24)34-21-37(30)26-16-27(40-18-23-12-6-2-7-13-23)25(29(26)38)20-39-17-22-10-4-1-5-11-22/h1-15,21,25-27,29,38H,16-20H2,(H2,33,35,36)/t25-,26+,27+,29+/m1/s1

Upstream product

• 110567-22-1 (2R,3S)-benzyloxy-2-benzyloxymethyl-6-oxabicyclo<3.1.0>hexane 
• 19916-73-5 2-Amino-6-benzyloxypurine 
• 3587-60-8 Benzyloxymethyl chloride 
• 39939-07-6 5-(benzyloxymethyl)cyclopentadiene 
• 117641-39-1 (2R,3S)-2-benzyloxymethyl-6-oxabicyclo<3.1.0>hexan-3-ol 
• 110567-21-0 (1S,2R)-2-(benzyloxymethyl)-1-hydroxy-3-cyclopentene 
• 4984-82-1 sodium cyclopentadienylide 

Downstream Products

• 142217-78-5 (1S,2S,3S,5S)-5-[2-[[(4-methoxyphenyl)diphenylmethyl]amino]-6-benzyloxy-9H-purin-9-yl]-3-benzyloxy-2-[(benzyloxy)methyl]cyclopentanol 
• 142217-81-0 2-amino-1,9-dihydro-9-[(1S,3R,4S)-2-methylene-4-(phenylmethoxy)-3-[(phenylmethoxy)methyl]cyclopentyl]-6H-purin-6-one 
• 142217-69-4 entecavir 
• 142217-79-6 (2R,3S,5S)-5-[2-[[(4-methoxyphenyl)diphenylmethyl]amino]-6-benzyloxy-9H-fluoren-9-yl]-3-benzyloxy-2-[(benzyloxy)methyl]cyclopentanone 
• 142217-80-9 6-(benzyloxy)-9-((1S,3R,4S)-4-(benzyloxy)-3-((benzyloxy)methyl)-2-methylidenecyclopentyl)-N-((4-methoxyphenyl)diphenylmethyl)-9H-purin-2-amine 
• 1006053-47-9 [1S-(1α,2β,3α,5β)]-5-(2-acetylamino-6-benzyloxy-9H-purin-9-yl)-3-benzyloxy-2-(benzyloxy)methyl-cyclopentanol 

Relevant articles and documents

Method for synthesizing Entecavir intermediate

The invention relates to a method for synthesizing an Entecavir intermediate and particularly relates to a method for synthesizing a compound represented by a formula I. According to the method, firstly, amino of 6-benzyloxy guanine is protected, and thus

BMS-200475, a novel carbocyclic 2'-deoxyguanosine analog with potent and selective anti-hepatitis B virus activity in vitro

BMS-200475, a never carbocyclic analog of 2'-deoxyguanosine, is a potent inhibitor of hepatitis B virus in vitro (ED50 = 3 nM) with relatively low cytotoxicity (CC50 = 21-120 μM). A practical 10-step asymmetric synthesis was developed affording BMS-200475 in 18% overall chemical yield and > 99% optical purity. The enantiomer of BMS-200475 as well as the adenine, thymine, and iodouracil analogs are much less active.